The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of four new members to its Executive Committee – including John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Terms begin after the 2016 ASH Annual Meeting December 3-6 in San Diego.
Byrd is a distinguished university professor of medicine, pharmaceutics, and veterinary bioscience; D. Warren Brown Chair of Leukemia Research, and the director of the Division of Hematology at the OSUCCC – James. He also serves as co-leader of the OSUCCC – James Leukemia Research Program and is principal investigator on multiple grants from the National Cancer Institute related to his work in leukemia.
Byrd’s research interests include pre-clinical and clinical targeted therapy development in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and molecular and immune pharmacology. Dr. Byrd is also a principal on the Leukemia Lymphoma Society’s AML umbrella study that has recently been initiated. Dr. Byrd has served as a reviewer and/or coordinator of ASH Annual Meeting abstracts for over a decade and has served as an ASH Clinical Research Training Institute faculty member from 2005 – 2012, serving as co-director from 2009 – 2011. He has also served as a contributing editor for The Hematologist, and he is currently an associate editor of Blood. He was also the 2015 recipient of the 2015 William Dameshek Prize for his contributions to the development of transformative treatments for CLL.